Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?

被引:16
|
作者
Luo, Nan [1 ]
Cheung, Yin Bun [2 ,3 ,4 ]
Ng, Raymond [5 ]
Lee, Chun Fan [2 ,3 ]
机构
[1] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore
[2] Duke NUS Grad Med Sch, Ctr Quantitat Med, Singapore, Singapore
[3] Singapore Clin Res Inst, Dept Biostat, Singapore, Singapore
[4] Univ Tampere, Dept Int Hlth, FIN-33101 Tampere, Finland
[5] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
来源
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
QUALITY-OF-LIFE; BREAST-CANCER PATIENTS; FUNCTIONAL ASSESSMENT; CHINESE VERSIONS; FACT-B; DIABETES PATIENTS; UTILITY INDEX; HEALTH; QUESTIONNAIRE; THERAPY;
D O I
10.1186/s12955-015-0361-y
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Utility values of health states defined by health-related quality of life instruments can be derived from either direct valuation ('valuation-derived') or mapping ('mapping-derived'). This study aimed to compare the utility-based EQ-5D-5L index scores derived from the two approaches as a means to validating the mapping function developed by van Hout et al for the EQ-5D-5L instrument. Methods: This was an observational study of 269 breast cancer patients whose EQ-5D-5L index scores were derived from both methods. For comparing discriminatory ability and responsiveness to change, multivariable regression models were used to estimate the effect sizes of various health indicators on the index scores. Agreement and test-retest reliability were examined using intraclass correlation coefficient (ICC). Whenever appropriate, the 90 % confidence intervals (90 % CI) were compared to predefined equivalence margins. Results: The mean difference in and ICC between the valuation-and mapping-derived EQ-5D-5L index scores were 0.015 (90 % CI = 0.006 to 0.024) and 0.915, respectively. Discriminatory ability and responsiveness of the two indices were equivalent in 13 of 15 regression analyses. However, the mapping-derived index score was lower than the valuation-derived index score in patients experiencing extreme health problems, and the test-retest reliability of the former was lower than the latter, for example, their ICCs differed by 0.121 (90 % CI = 0.051 to 0.198) in patients who reported no change in performance status in the follow-up survey. Conclusion: This study provided the first evidence supporting the validity of the mapping function for converting EQ-5D-5L profile data into a utility-based index score.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] The EQ-5D-5L valuation study for Trinidad and Tobago
    Bailey, Henry
    Jonker, Marcel F.
    Pullenayegum, Eleanor
    Rencz, Fanni
    Roudijk, Bram
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2024, 22 (01)
  • [22] Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol
    Stolk, Elly
    Ludwig, Kristina
    Rand, Kim
    van Hout, Ben
    Ramos-Goni, Juan Manuel
    VALUE IN HEALTH, 2019, 22 (01) : 23 - 30
  • [23] A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index
    Su, Juan
    Liu, Tong
    Li, Shunping
    Zhao, Yue
    Kuang, Yehong
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 737 - 743
  • [24] AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SET
    Cooper, S.
    Bouvy, J.
    Boysen, M.
    Robertson, J.
    VALUE IN HEALTH, 2018, 21 : S84 - S85
  • [25] The development of new research methods for the valuation of EQ-5D-5L
    Nancy J. Devlin
    Paul F. M. Krabbe
    The European Journal of Health Economics, 2013, 14 : 1 - 3
  • [26] Choice Defines QALYs A US Valuation of the EQ-5D-5L
    Craig, Benjamin M.
    Rand, Kim
    MEDICAL CARE, 2018, 56 (06) : 529 - 536
  • [27] Toward a Smaller Design for EQ-5D-5L Valuation Studies
    Yang, Zhihao
    Luo, Nan
    Oppe, Mark
    Bonsel, Gouke
    Busschbach, Jan
    Stolk, Elly
    VALUE IN HEALTH, 2019, 22 (11) : 1295 - 1302
  • [28] The development of new research methods for the valuation of EQ-5D-5L
    Devlin, Nancy J.
    Krabbe, Paul F. M.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 : S1 - S3
  • [29] Retraction Note to: The EQ-5D-5L Valuation Study in Egypt
    Sahar A. Al Shabasy
    Maggie M. Abbassi
    Aureliano Paolo Finch
    Darrin Baines
    Samar F. Farid
    PharmacoEconomics, 2021, 39 : 971 - 971
  • [30] CHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L
    Craig, B. M.
    Rand, K.
    VALUE IN HEALTH, 2018, 21 : S12 - S12